{
    "id": 5309,
    "date": "2026-11-12T19:56:19",
    "date_gmt": "2026-11-12T18:56:19",
    "guid": {
        "rendered": "https:\/\/www.phinc-group.com\/?p=5309"
    },
    "modified": "2026-11-12T21:48:55",
    "modified_gmt": "2026-11-12T20:48:55",
    "slug": "equilibrer-lefficacite-et-la-securite-en-oncologie",
    "status": "publish",
    "type": "post",
    "link": "https:\/\/www.phinc-group.com\/fr\/equilibrer-lefficacite-et-la-securite-en-oncologie\/",
    "title": {
        "rendered": "\u00c9quilibrer l’Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie"
    },
    "content": {
        "rendered": "<div data-elementor-type=\"wp-post\" data-elementor-id=\"5309\" class=\"elementor elementor-5309\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-67a5bd8 e-con-full e-flex e-con e-parent\" data-id=\"67a5bd8\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-73b996f elementor-widget elementor-widget-html\" data-id=\"73b996f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"onco-page\">\r\n<style>\r\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Cormorant+Garamond:ital,wght@0,300;0,500;1,300&family=Poppins:wght@200;300;400;600;700&display=swap');\r\n\r\n.onco-page{\r\n  --phinc-blue:#00005f;\r\n  --phinc-pink:#d94b9f;\r\n  --ink:#0F172A;\r\n  --muted:#475569;\r\n  --line:#E6EAF2;\r\n  --bg:#F7F9FC;\r\n  --card:#FFFFFF;\r\n  --radius:18px;\r\n  --shadow: 0 10px 30px rgba(15,23,42,.08);\r\n  background:var(--bg);\r\n  color:var(--ink);\r\n  font-family:'Poppins',Arial,sans-serif;\r\n  -webkit-font-smoothing:antialiased;\r\n}\r\n.onco-page *{box-sizing:border-box;}\r\n.onco-page em{font-style:normal;color:var(--phinc-pink);}\r\n.onco-page .onco-container{max-width:1080px;margin:0 auto;padding:0 32px;}\r\n\r\n\/* ---------- HERO ---------- *\/\r\n.onco-hero{padding:88px 0 64px;}\r\n.onco-hero-grid{display:grid;grid-template-columns:1.1fr 0.9fr;gap:48px;align-items:center;}\r\n.onco-eyebrow{\r\n  display:inline-flex;align-items:center;gap:8px;\r\n  padding:8px 18px;border-radius:999px;\r\n  background:linear-gradient(135deg, rgba(0,0,95,.06), rgba(217,75,159,.10));\r\n  border:1px solid var(--line);\r\n  font-family:'Poppins',sans-serif;font-weight:600;font-size:12px;\r\n  letter-spacing:.14em;text-transform:uppercase;color:var(--phinc-blue);\r\n  margin-bottom:28px;\r\n}\r\n.onco-eyebrow .onco-dot{\r\n  width:8px;height:8px;border-radius:50%;\r\n  background:linear-gradient(135deg, var(--phinc-blue), var(--phinc-pink));\r\n  display:inline-block;\r\n}\r\n.onco-hero h1{\r\n  font-family:'Cormorant Garamond',serif;font-weight:300;\r\n  font-size:44px;line-height:1.16;color:var(--phinc-blue);\r\n  margin:0 0 20px;max-width:600px;text-wrap:balance;\r\n}\r\n.onco-hero .onco-standfirst{\r\n  font-family:'Poppins',sans-serif;font-weight:200;font-size:14.5px;line-height:1.75;\r\n  color:var(--muted);margin:0 0 24px;max-width:540px;\r\n}\r\n.onco-meta-row{display:flex;flex-wrap:wrap;gap:10px;}\r\n.onco-meta-pill{\r\n  padding:7px 16px;border-radius:999px;border:1px solid var(--line);\r\n  background:#fff;font-size:13px;font-weight:600;color:var(--phinc-blue);\r\n}\r\n\r\n\/* ---------- VISUELS ---------- *\/\r\n.onco-visual{\r\n  position:relative;width:100%;border-radius:var(--radius);overflow:hidden;\r\n  border:1px solid var(--line);box-shadow:var(--shadow);\r\n  background:linear-gradient(135deg, rgba(0,0,95,.06), rgba(217,75,159,.08));\r\n}\r\n.onco-visual img{display:block;width:100%;height:100%;object-fit:cover;}\r\n.onco-ai-credit{\r\n  position:absolute;right:12px;bottom:10px;z-index:3;\r\n  font-family:'Poppins',sans-serif;font-weight:400;font-size:10.5px;\r\n  letter-spacing:.04em;color:rgba(255,255,255,.88);\r\n  background:rgba(15,23,42,.38);backdrop-filter:blur(4px);\r\n  padding:4px 10px;border-radius:999px;line-height:1.3;pointer-events:none;\r\n}\r\n.onco-visual.hero-visual{aspect-ratio:4\/3;}\r\n.onco-visual.wide{aspect-ratio:16\/9;margin:40px 0;}\r\n\r\n\/* ---------- DIVIDER ---------- *\/\r\n.onco-divider{border:none;border-top:1px solid var(--line);margin:8px 0 56px;}\r\n\r\n\/* ---------- SECTIONS ---------- *\/\r\n.onco-section{padding:8px 0 56px;}\r\n.onco-kicker{\r\n  display:block;font-family:'Poppins',sans-serif;font-weight:700;\r\n  font-size:12px;letter-spacing:.14em;text-transform:uppercase;\r\n  color:var(--phinc-pink);margin-bottom:14px;\r\n}\r\n.onco-section h2{\r\n  font-family:'Cormorant Garamond',serif;font-weight:300;font-size:38px;\r\n  color:var(--phinc-blue);margin:0 0 28px;max-width:900px;\r\n}\r\n.onco-section h3{\r\n  font-family:'Poppins',sans-serif;font-weight:600;font-size:19px;\r\n  color:var(--ink);margin:0 0 10px;\r\n}\r\n.onco-section p{\r\n  font-family:'Poppins',sans-serif;font-weight:300;font-size:16px;\r\n  line-height:1.85;color:var(--muted);margin:0 0 18px;\r\n}\r\n.onco-section strong{font-weight:600;color:var(--ink);}\r\n.onco-section sup{font-size:11px;font-weight:600;color:var(--phinc-pink);}\r\n\r\n\/* ---------- BASCULE MTD \/ DOSE OPTIMIS\u00c9E ---------- *\/\r\n.onco-compare{display:grid;grid-template-columns:1fr 1fr;gap:24px;margin:36px 0;}\r\n.onco-compare > div{\r\n  background:var(--card);border:1px solid var(--line);border-left:3px solid #C7CEDE;\r\n  border-radius:var(--radius);box-shadow:var(--shadow);padding:30px 32px;\r\n}\r\n.onco-compare > div.onco-now{border-left-color:var(--phinc-pink);}\r\n.onco-compare-label{\r\n  font-family:'Poppins',sans-serif;font-weight:700;font-size:11.5px;\r\n  letter-spacing:.14em;text-transform:uppercase;color:var(--muted);margin:0 0 12px;\r\n}\r\n.onco-compare .onco-now .onco-compare-label{color:var(--phinc-pink);}\r\n.onco-compare p:last-child{margin-bottom:0;}\r\n\r\n\/* ---------- CARTES \u00ab ARR\u00caTEZ DE \u00bb ---------- *\/\r\n.onco-cards{display:grid;grid-template-columns:repeat(3,1fr);gap:24px;margin:36px 0;}\r\n.onco-card{\r\n  background:var(--card);border:1px solid var(--line);border-radius:var(--radius);\r\n  box-shadow:var(--shadow);padding:32px 28px;\r\n}\r\n.onco-icon-chip{\r\n  width:48px;height:48px;border-radius:12px;margin-bottom:20px;\r\n  display:flex;align-items:center;justify-content:center;font-size:22px;\r\n  background:linear-gradient(135deg, rgba(0,0,95,.10), rgba(217,75,159,.14));\r\n  color:var(--phinc-blue);\r\n}\r\n.onco-stop{\r\n  font-family:'Poppins',sans-serif;font-weight:600;font-size:12px;\r\n  letter-spacing:.1em;text-transform:uppercase;color:var(--phinc-pink);\r\n  display:block;margin-bottom:8px;\r\n}\r\n.onco-card h3{font-size:18px;}\r\n.onco-card p{font-size:14.5px;line-height:1.75;margin-bottom:0;}\r\n\r\n\/* ---------- CAS D'USAGE : BARRES ---------- *\/\r\n.onco-uses{display:flex;flex-direction:column;gap:16px;margin:36px 0 0;}\r\n.onco-use{\r\n  display:grid;grid-template-columns:56px minmax(0,1fr);gap:24px;align-items:start;\r\n  background:var(--card);border:1px solid var(--line);border-radius:var(--radius);\r\n  box-shadow:var(--shadow);padding:28px 32px;\r\n}\r\n.onco-use-mark{\r\n  width:48px;height:48px;border-radius:12px;\r\n  display:flex;align-items:center;justify-content:center;\r\n  font-family:'Cormorant Garamond',serif;font-size:24px;color:#fff;\r\n  background:linear-gradient(135deg, var(--phinc-blue), var(--phinc-pink));\r\n}\r\n.onco-use p:last-child{margin-bottom:0;}\r\n\r\n\/* ---------- PULL QUOTE ---------- *\/\r\n.onco-quote{\r\n  position:relative;overflow:hidden;\r\n  background:linear-gradient(135deg, rgba(0,0,95,.05), rgba(217,75,159,.08));\r\n  border:1px solid var(--line);border-radius:var(--radius);\r\n  padding:48px 56px;margin:48px 0;\r\n}\r\n.onco-section > .onco-quote:last-child{margin-bottom:0;}\r\n.onco-quote .onco-quote-mark{\r\n  position:absolute;top:-30px;left:16px;\r\n  font-family:'Cormorant Garamond',serif;font-size:180px;\r\n  color:var(--phinc-pink);opacity:.12;line-height:1;\r\n}\r\n.onco-quote p{\r\n  position:relative;font-family:'Cormorant Garamond',serif;font-style:italic;\r\n  font-weight:300;font-size:22px;line-height:1.6;color:var(--phinc-blue);margin:0;\r\n}\r\n\r\n\/* ---------- BONNES PRATIQUES ---------- *\/\r\n.onco-practice{display:flex;gap:20px;padding:26px 0;border-bottom:1px solid var(--line);}\r\n.onco-practice:last-child{border-bottom:none;}\r\n.onco-practice-num{\r\n  font-family:'Cormorant Garamond',serif;font-weight:300;font-size:40px;\r\n  color:var(--phinc-pink);line-height:1;min-width:56px;\r\n}\r\n.onco-practice p{margin:0;}\r\n\r\n\/* ---------- R\u00c9F\u00c9RENCES ---------- *\/\r\n.onco-refs{\r\n  background:var(--card);border:1px solid var(--line);border-radius:var(--radius);\r\n  padding:32px 36px;margin-top:20px;\r\n}\r\n.onco-refs ol{margin:0;padding-left:20px;}\r\n.onco-refs li{\r\n  font-family:'Poppins',sans-serif;font-weight:300;font-size:13.5px;\r\n  color:var(--muted);line-height:1.8;margin-bottom:10px;\r\n}\r\n.onco-refs em{font-style:italic;}\r\n.onco-refs a{color:var(--phinc-blue);text-decoration:none;word-break:break-all;}\r\n.onco-refs a:hover{text-decoration:underline;}\r\n\r\n\/* ---------- CTA SUR VISUEL ---------- *\/\r\n.onco-cta{\r\n  position:relative;overflow:hidden;border-radius:var(--radius);\r\n  background-color:var(--phinc-blue);background-size:cover;background-position:center;\r\n  min-height:440px;\r\n  display:flex;flex-direction:column;align-items:center;justify-content:center;\r\n  padding:88px 56px;text-align:center;margin:24px 0 96px;\r\n}\r\n.onco-cta::before{\r\n  content:\"\";position:absolute;inset:0;\r\n  background:linear-gradient(135deg, rgba(0,0,95,.86) 0%, rgba(0,0,95,.60) 55%, rgba(74,21,96,.55) 100%);\r\n}\r\n.onco-cta::after{\r\n  content:\"\";position:absolute;top:-140px;right:-110px;width:360px;height:360px;\r\n  border-radius:50%;background:radial-gradient(circle, rgba(217,75,159,.45), transparent 70%);\r\n}\r\n.onco-cta h2{\r\n  position:relative;font-family:'Cormorant Garamond',serif;font-weight:300;\r\n  font-size:42px;color:#fff;margin:0 0 18px;max-width:760px;\r\n  text-shadow:0 2px 24px rgba(0,0,40,.45);\r\n}\r\n.onco-cta h2 em{color:#f9b8e4;}\r\n.onco-cta p{\r\n  position:relative;font-family:'Poppins',sans-serif;font-weight:300;font-size:16px;\r\n  color:rgba(255,255,255,.92);max-width:620px;margin:0 auto 36px;line-height:1.7;\r\n  text-shadow:0 1px 16px rgba(0,0,40,.45);\r\n}\r\n.onco-cta-buttons{position:relative;display:flex;gap:16px;justify-content:center;flex-wrap:wrap;}\r\n.onco-btn{\r\n  font-family:'Poppins',sans-serif;font-weight:600;font-size:14.5px;\r\n  padding:14px 30px;border-radius:12px;text-decoration:none;display:inline-block;\r\n}\r\n.onco-btn.primary{background:var(--phinc-pink);color:#fff;box-shadow:0 8px 20px rgba(217,75,159,.4);}\r\n.onco-btn.ghost{\r\n  background:rgba(255,255,255,.12);color:#fff;\r\n  border:1px solid rgba(255,255,255,.6);backdrop-filter:blur(6px);\r\n}\r\n\r\n@media (max-width:980px){\r\n  .onco-cards{grid-template-columns:1fr;}\r\n  .onco-compare{grid-template-columns:1fr;}\r\n}\r\n@media (max-width:860px){\r\n  .onco-hero{padding:64px 0 40px;}\r\n  .onco-hero-grid{grid-template-columns:1fr;}\r\n  .onco-hero h1{font-size:34px;max-width:100%;}\r\n  .onco-hero .onco-standfirst{max-width:100%;}\r\n  .onco-use{grid-template-columns:1fr;gap:16px;}\r\n  .onco-quote{padding:36px 28px;}\r\n  .onco-cta{padding:56px 28px;min-height:360px;}\r\n}\r\n<\/style>\r\n\r\n<div class=\"onco-container\">\r\n\r\n  <!-- HERO -->\r\n  <section class=\"onco-hero\">\r\n    <div class=\"onco-hero-grid\">\r\n      <div>\r\n        <span class=\"onco-eyebrow\"><span class=\"onco-dot\"><\/span>Oncologie &amp; MIDD<\/span>\r\n        <h1>\u00c9quilibrer l'efficacit\u00e9 et la s\u00e9curit\u00e9 en oncologie&nbsp;: connecter les mod\u00e8les \u00e0 la <em>qualit\u00e9 de vie<\/em><\/h1>\r\n        <p class=\"onco-standfirst\">De la dose maximale tol\u00e9r\u00e9e \u00e0 la dose optimis\u00e9e : comment la mod\u00e9lisation relie exposition, toxicit\u00e9 et vie quotidienne du patient.<\/p>\r\n        <div class=\"onco-meta-row\">\r\n          <span class=\"onco-meta-pill\">Projet Optimus \u00b7 ICH M15<\/span>\r\n          <span class=\"onco-meta-pill\">PopPK \u00b7 QSP \u00b7 PK\/PD<\/span>\r\n          <span class=\"onco-meta-pill\">Qualit\u00e9 de vie<\/span>\r\n        <\/div>\r\n      <\/div>\r\n      <!-- VISUEL IMG-01 -->\r\n      <figure class=\"onco-visual hero-visual\">\r\n        <img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/11\/visuel-efficacite-et-tolerance.png\"\r\n             alt=\"\u00c9quilibre entre efficacit\u00e9 et tol\u00e9rance dans la d\u00e9cision de dose\"\r\n             width=\"1200\" height=\"900\">\r\n       \r\n      <\/figure>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <hr class=\"onco-divider\">\r\n\r\n  <!-- SECTION 1 -->\r\n  <section class=\"onco-section\">\r\n    <span class=\"onco-kicker\">Contexte<\/span>\r\n    <h2>Le changement de paradigme dans le d\u00e9veloppement en <em>oncologie<\/em><\/h2>\r\n    <p>Au cours de la derni\u00e8re d\u00e9cennie, le d\u00e9veloppement de m\u00e9dicaments en oncologie est pass\u00e9 d'une forte d\u00e9pendance \u00e0 la \u00ab dose maximale tol\u00e9r\u00e9e \u00bb (MTD) \u00e0 un encouragement actif des approches sur mesure inform\u00e9es par la mod\u00e9lisation. La Food and Drug Administration (FDA) des \u00c9tats-Unis a officialis\u00e9 ses attentes par le biais d'initiatives sp\u00e9cifiques comme le <strong>Projet Optimus<\/strong>, poussant \u00e0 une optimisation des doses qui \u00e9quilibre efficacit\u00e9 et toxicit\u00e9 <sup>[1]<\/sup>.<\/p>\r\n\r\n    <div class=\"onco-compare\">\r\n      <div>\r\n        <p class=\"onco-compare-label\">Hier \u2014 la dose maximale tol\u00e9r\u00e9e<\/p>\r\n        <p>Une dose pouss\u00e9e jusqu'\u00e0 la limite de la tol\u00e9rance, au risque d'une exposition continue dont le patient paie le prix au long cours.<\/p>\r\n      <\/div>\r\n      <div class=\"onco-now\">\r\n        <p class=\"onco-compare-label\">Aujourd'hui \u2014 la dose optimis\u00e9e<\/p>\r\n        <p>Une dose justifi\u00e9e par la mod\u00e9lisation, qui \u00e9quilibre efficacit\u00e9 et toxicit\u00e9 et traite la qualit\u00e9 de vie comme un co-objectif principal.<\/p>\r\n      <\/div>\r\n    <\/div>\r\n\r\n    <p>De m\u00eame, les autorit\u00e9s sanitaires mondiales s'engagent aupr\u00e8s des promoteurs pour mettre en \u0153uvre les m\u00e9thodologies de d\u00e9veloppement de m\u00e9dicaments inform\u00e9 par la mod\u00e9lisation (MIDD) selon des directives telles que l'ICH M15 <sup>[2]<\/sup>. Elles attendent que la s\u00e9lection des doses soit <strong>rigoureusement param\u00e9tr\u00e9e, parfaitement transparente et justifi\u00e9e sur le plan m\u00e9canistique<\/strong>, garantissant ainsi que les d\u00e9cisions relatives au portefeuille de d\u00e9veloppement reposent effectivement sur des fondements pharmacom\u00e9triques.<\/p>\r\n  <\/section>\r\n\r\n  <hr class=\"onco-divider\">\r\n\r\n  <!-- SECTION 2 -->\r\n  <section class=\"onco-section\">\r\n    <span class=\"onco-kicker\">Attentes r\u00e9glementaires<\/span>\r\n    <h2>Trois exigences en mati\u00e8re de <em>mod\u00e9lisation m\u00e9canistique<\/em><\/h2>\r\n\r\n    <div class=\"onco-cards\">\r\n      <div class=\"onco-card\">\r\n        <div class=\"onco-icon-chip\">\u25d4<\/div>\r\n        <span class=\"onco-stop\">Arr\u00eatez de doser pour la moyenne<\/span>\r\n        <h3>Pharmacocin\u00e9tique de population (PopPK)<\/h3>\r\n        <p>Un principe r\u00e9glementaire fondamental est que le dosage doit tenir compte de la diversit\u00e9 r\u00e9elle des patients. Les promoteurs sont cens\u00e9s g\u00e9n\u00e9rer des mod\u00e8les PopPK robustes qui s'ajustent aux variations de poids, d'\u00e2ge et de g\u00e9n\u00e9tique, garantissant que les sous-populations vuln\u00e9rables re\u00e7oivent des dosages optimis\u00e9s <sup>[4]<\/sup>.<\/p>\r\n      <\/div>\r\n      <div class=\"onco-card\">\r\n        <div class=\"onco-icon-chip\">\u25c7<\/div>\r\n        <span class=\"onco-stop\">Arr\u00eatez de deviner pourquoi la Phase III a \u00e9chou\u00e9<\/span>\r\n        <h3>Pharmacologie quantitative des syst\u00e8mes (QSP)<\/h3>\r\n        <p>Les r\u00e9gulateurs et les promoteurs s'appuient de plus en plus sur la QSP pour simuler les boucles de r\u00e9troaction complexes des tumeurs avant m\u00eame l'enr\u00f4lement du premier patient. En mod\u00e9lisant ces r\u00e9seaux biologiques dynamiques, les d\u00e9veloppeurs peuvent pr\u00e9dire les m\u00e9canismes de r\u00e9sistance et anticiper avec pr\u00e9cision les r\u00e9sultats cliniques.<\/p>\r\n      <\/div>\r\n      <div class=\"onco-card\">\r\n        <div class=\"onco-icon-chip\">\u25ce<\/div>\r\n        <span class=\"onco-stop\">Arr\u00eatez de masquer les limites<\/span>\r\n        <h3>Int\u00e9gration PK\/PD : la \u00ab zone Boucles d'or \u00bb<\/h3>\r\n        <p>Tout programme en oncologie doit d\u00e9finir un espace de s\u00e9curit\u00e9 o\u00f9 l'efficacit\u00e9 est maximis\u00e9e et la toxicit\u00e9 minimis\u00e9e. Les autorit\u00e9s s'attendent \u00e0 ce que les promoteurs cartographient la relation exacte entre la concentration du m\u00e9dicament et la r\u00e9ponse biologique <sup>[5]<\/sup>. Masquer les limites de cette zone ou omettre d'int\u00e9grer des biomarqueurs de s\u00e9curit\u00e9 est un signal d'alarme pour les \u00e9valuateurs.<\/p>\r\n      <\/div>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <hr class=\"onco-divider\">\r\n\r\n  <!-- SECTION 3 -->\r\n  <section class=\"onco-section\">\r\n    <span class=\"onco-kicker\">Cas d'utilisation<\/span>\r\n    <h2>O\u00f9 le MIDD a le <em>plus d'impact<\/em> dans un programme clinique<\/h2>\r\n    <p>Comprendre o\u00f9 les organismes de r\u00e9glementation sont les plus r\u00e9ceptifs au MIDD peut aider les promoteurs \u00e0 prioriser leurs efforts quantitatifs.<\/p>\r\n\r\n    <div class=\"onco-uses\">\r\n      <div class=\"onco-use\">\r\n        <span class=\"onco-use-mark\">01<\/span>\r\n        <div>\r\n          <h3>S\u00e9lection de dose individualis\u00e9e<\/h3>\r\n          <p>Il existe un mandat strict pour s'\u00e9loigner des doses maximales arbitraires. Les autorit\u00e9s r\u00e9glementaires s'attendent d\u00e9sormais \u00e0 une mod\u00e9lisation robuste pour justifier la dose recommand\u00e9e pour la Phase 2 (RP2D), garantissant qu'une exposition continue n'a pas d'impact n\u00e9gatif sur la s\u00e9curit\u00e9 clinique \u00e0 long terme ou la qualit\u00e9 de vie <sup>[1]<\/sup>.<\/p>\r\n        <\/div>\r\n      <\/div>\r\n      <div class=\"onco-use\">\r\n        <span class=\"onco-use-mark\">02<\/span>\r\n        <div>\r\n          <h3>Mod\u00e9lisation pr\u00e9dictive des interactions m\u00e9dicamenteuses (DDI)<\/h3>\r\n          <p>Les patients en oncologie ne vivent pas en vase clos. Si un m\u00e9dicament anticanc\u00e9reux interagit mal avec leurs autres traitements, l'observance comme les donn\u00e9es de l'essai s'effondrent. Les mod\u00e8les DDI pr\u00e9dictifs comblent le foss\u00e9 entre les conditions d'essai isol\u00e9es et la polypharmacie du monde r\u00e9el <sup>[3]<\/sup>.<\/p>\r\n        <\/div>\r\n      <\/div>\r\n      <div class=\"onco-use\">\r\n        <span class=\"onco-use-mark\">03<\/span>\r\n        <div>\r\n          <h3>Essais virtuels et simulation<\/h3>\r\n          <p>Le MIDD est une pierre angulaire de la gestion du cycle de vie. Les organismes de r\u00e9glementation acceptent couramment les essais simul\u00e9s pour \u00e9valuer des sch\u00e9mas posologiques alternatifs, minimisant ainsi le besoin d'exposer des patients vuln\u00e9rables \u00e0 des bras exp\u00e9rimentaux inutiles <sup>[2]<\/sup>.<\/p>\r\n        <\/div>\r\n      <\/div>\r\n    <\/div>\r\n\r\n    <!-- VISUEL IMG-02 -->\r\n    <figure class=\"onco-visual wide\">\r\n      <img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/11\/Medecin-devant-des-courbes-lumineuses.png\"\r\n           alt=\"M\u00e9decin analysant des courbes d'exposition et de r\u00e9ponse sur un grand \u00e9cran\"\r\n           width=\"1600\" height=\"900\">\r\n      <span class=\"onco-ai-credit\">Image g\u00e9n\u00e9r\u00e9e par IA<\/span>\r\n    <\/figure>\r\n  <\/section>\r\n\r\n  <hr class=\"onco-divider\">\r\n\r\n  <!-- SECTION 4 -->\r\n  <section class=\"onco-section\">\r\n    <span class=\"onco-kicker\">Meilleures pratiques<\/span>\r\n    <h2>Ce que les <em>promoteurs<\/em> doivent mettre en place<\/h2>\r\n    <p>Pour naviguer avec succ\u00e8s dans ces attentes r\u00e9glementaires, les \u00e9quipes de pharmacologie clinique et les pharmacom\u00e9triciens devraient adopter les meilleures pratiques suivantes :<\/p>\r\n\r\n    <div class=\"onco-practice\">\r\n      <span class=\"onco-practice-num\">01<\/span>\r\n      <div>\r\n        <h3>S'engager t\u00f4t<\/h3>\r\n        <p>N'attendez pas la soumission de la NDA\/BLA pour introduire des mod\u00e8les complexes. Utilisez les r\u00e9unions avec les agences r\u00e9glementaires, comme le programme de r\u00e9unions MIDD de la FDA, pour obtenir un alignement pr\u00e9coce sur la strat\u00e9gie de mod\u00e9lisation et l'application r\u00e9glementaire pr\u00e9vue <sup>[3]<\/sup>.<\/p>\r\n      <\/div>\r\n    <\/div>\r\n    <div class=\"onco-practice\">\r\n      <span class=\"onco-practice-num\">02<\/span>\r\n      <div>\r\n        <h3>Adopter les math\u00e9matiques et param\u00e9trer avec rigueur<\/h3>\r\n        <p>Tout comme les essais cliniques n\u00e9cessitent une planification minutieuse, les efforts de mod\u00e9lisation destin\u00e9s \u00e0 la prise de d\u00e9cision r\u00e9glementaire doivent \u00eatre r\u00e9gis par un plan pr\u00e9sp\u00e9cifi\u00e9. Les donn\u00e9es d'entr\u00e9e doivent \u00eatre mesur\u00e9es avec soin, et les relations math\u00e9matiques fortement justifi\u00e9es pour renforcer la confiance des autorit\u00e9s.<\/p>\r\n      <\/div>\r\n    <\/div>\r\n    <div class=\"onco-practice\">\r\n      <span class=\"onco-practice-num\">03<\/span>\r\n      <div>\r\n        <h3>Favoriser la collaboration interfonctionnelle<\/h3>\r\n        <p>Une soumission MIDD r\u00e9ussie est rarement le produit d'un seul scientifique. Elle n\u00e9cessite une int\u00e9gration \u00e9troite entre les oncologues, les pharmacom\u00e9triciens et les concepteurs d'essais. Le rapport final doit traduire des r\u00e9sultats math\u00e9matiques complexes en informations cliniques claires et exploitables, ax\u00e9es sur l'esp\u00e9rance de vie en bonne sant\u00e9 du patient.<\/p>\r\n      <\/div>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <hr class=\"onco-divider\">\r\n\r\n  <!-- CONCLUSION -->\r\n  <section class=\"onco-section\">\r\n    <span class=\"onco-kicker\">Conclusion<\/span>\r\n    <h2>La qualit\u00e9 de vie comme <em>co-objectif principal<\/em><\/h2>\r\n    <p>Alors que le d\u00e9veloppement de m\u00e9dicaments en oncologie devient de plus en plus complexe, le succ\u00e8s ne se trouve plus uniquement sur la paillasse du laboratoire : il se trouve dans les mod\u00e8les. Le MIDD offre une voie scientifiquement rigoureuse pour r\u00e9duire les risques des essais cliniques et acc\u00e9l\u00e9rer l'acc\u00e8s des patients \u00e0 des th\u00e9rapies salvatrices et tol\u00e9rables.<\/p>\r\n\r\n    <div class=\"onco-quote\">\r\n      <span class=\"onco-quote-mark\">&rdquo;<\/span>\r\n      <p>En adh\u00e9rant aux attentes r\u00e9glementaires mondiales, en mettant l'accent sur une validation PK\/PD robuste et en traitant la qualit\u00e9 de vie comme un co-objectif principal, les promoteurs peuvent transformer leurs mod\u00e8les pharmacom\u00e9triques d'exercices exploratoires en atouts r\u00e9glementaires d\u00e9cisifs.<\/p>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <!-- CTA pos\u00e9 sur le visuel IMG-03 -->\r\n  <section class=\"onco-cta\" style=\"background-image:url('https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/11\/Reunion-medicale-lumineuse-autour-dun-ordinateur-portable.png');\">\r\n    <h2>Optimisez la dose sans sacrifier la <em>qualit\u00e9 de vie<\/em><\/h2>\r\n    <p>L'\u00e9quipe PhinC accompagne les promoteurs en oncologie : mod\u00e8les PopPK et QSP, cartographie PK\/PD de la fen\u00eatre th\u00e9rapeutique, pr\u00e9diction des interactions m\u00e9dicamenteuses et essais simul\u00e9s.<\/p>\r\n    <div class=\"onco-cta-buttons\">\r\n      <a href=\"\/fr\/midd\/\" class=\"onco-btn primary\">D\u00e9couvrir nos expertises<\/a>\r\n      <a href=\"\/fr\/contact\/\" class=\"onco-btn ghost\">Nous contacter<\/a>\r\n    <\/div>\r\n    \r\n  <\/section>\r\n\r\n  <!-- R\u00c9F\u00c9RENCES -->\r\n  <section class=\"onco-section\">\r\n    <span class=\"onco-kicker\">R\u00e9f\u00e9rences<\/span>\r\n    <div class=\"onco-refs\">\r\n      <ol>\r\n        <li>U.S. Food and Drug Administration (FDA). (2023). <em>Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases.<\/em> Guidance for Industry.<\/li>\r\n        <li>International Council for Harmonisation (ICH). (2026). <em>ICH M15 General Principles for Model-Informed Drug Development.<\/em><\/li>\r\n        <li>U.S. Food and Drug Administration (FDA). (2023). <em>Model-Informed Drug Development Paired Meeting Program.<\/em><\/li>\r\n        <li>Ribba, B., et al. (2014). A review of mixed-effects models of tumor growth and anticancer drug effects. <em>CPT: Pharmacometrics &amp; Systems Pharmacology<\/em>, 3(5), 113.<\/li>\r\n        <li>Excelra. (2024). <em>Quantitative Systems Pharmacology (QSP): Finding the Goldilocks Dose in Clinical Trials.<\/em><\/li>\r\n      <\/ol>\r\n    <\/div>\r\n  <\/section>\r\n\r\n<\/div>\r\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>",
        "protected": false
    },
    "excerpt": {
        "rendered": "<p>Au cours de la derni\u00e8re d\u00e9cennie, le d\u00e9veloppement de m\u00e9dicaments en oncologie est pass\u00e9 d&rsquo;une forte d\u00e9pendance \u00e0 la \u00ab dose maximale tol\u00e9r\u00e9e \u00bb (MTD) \u00e0 un encouragement actif des approches sur mesure inform\u00e9es par la mod\u00e9lisation. La FDA a officialis\u00e9 ses attentes par le biais d&rsquo;initiatives sp\u00e9cifiques comme le Projet Optimus poussant \u00e0 une optimisation des doses qui \u00e9quilibre efficacit\u00e9 et toxicit\u00e9.<\/p>",
        "protected": false
    },
    "author": 2,
    "featured_media": 5314,
    "comment_status": "closed",
    "ping_status": "closed",
    "sticky": false,
    "template": "",
    "format": "standard",
    "meta": {
        "_acf_changed": false,
        "footnotes": ""
    },
    "categories": [
        39,
        41
    ],
    "tags": [],
    "service-associe": [],
    "class_list": [
        "post-5309",
        "post",
        "type-post",
        "status-publish",
        "format-standard",
        "has-post-thumbnail",
        "hentry",
        "category-a-la-une",
        "category-expertise"
    ],
    "acf": [],
    "yoast_head": "<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u00c9quilibrer l&#039;Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie - PhinC Group<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.phinc-group.com\/fr\/equilibrer-lefficacite-et-la-securite-en-oncologie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00c9quilibrer l&#039;Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie - PhinC Group\" \/>\n<meta property=\"og:description\" content=\"Au cours de la derni\u00e8re d\u00e9cennie, le d\u00e9veloppement de m\u00e9dicaments en oncologie est pass\u00e9 d&#039;une forte d\u00e9pendance \u00e0 la \u00ab dose maximale tol\u00e9r\u00e9e \u00bb (MTD) \u00e0 un encouragement actif des approches sur mesure inform\u00e9es par la mod\u00e9lisation. La FDA a officialis\u00e9 ses attentes par le biais d&#039;initiatives sp\u00e9cifiques comme le Projet Optimus poussant \u00e0 une optimisation des doses qui \u00e9quilibre efficacit\u00e9 et toxicit\u00e9.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.phinc-group.com\/fr\/equilibrer-lefficacite-et-la-securite-en-oncologie\/\" \/>\n<meta property=\"og:site_name\" content=\"PhinC Group\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-12T18:56:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-12T20:48:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/11\/visuel-efficacite-et-tolerance.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"750\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mohamed Taourirt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mohamed Taourirt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/\"},\"author\":{\"name\":\"Mohamed Taourirt\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\"},\"headline\":\"\u00c9quilibrer l&rsquo;Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie\",\"datePublished\":\"2026-11-12T18:56:19+00:00\",\"dateModified\":\"2026-11-12T20:48:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/\"},\"wordCount\":1255,\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/visuel-efficacite-et-tolerance.png\",\"articleSection\":[\"A la une\",\"Expertise\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/\",\"name\":\"\u00c9quilibrer l'Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie - PhinC Group\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/visuel-efficacite-et-tolerance.png\",\"datePublished\":\"2026-11-12T18:56:19+00:00\",\"dateModified\":\"2026-11-12T20:48:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/visuel-efficacite-et-tolerance.png\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/visuel-efficacite-et-tolerance.png\",\"width\":1000,\"height\":750},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/equilibrer-lefficacite-et-la-securite-en-oncologie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.phinc-group.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c9quilibrer l&rsquo;Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"name\":\"PhinC Group\",\"description\":\"Quantitative Pharmacology Solutions &amp; Modeling\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\",\"name\":\"PhinC Group\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"width\":600,\"height\":600,\"caption\":\"PhinC Group\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\",\"name\":\"Mohamed Taourirt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"caption\":\"Mohamed Taourirt\"},\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/author\\\/mtaourirt\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->",
    "yoast_head_json": {
        "title": "\u00c9quilibrer l'Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie - PhinC Group",
        "robots": {
            "index": "index",
            "follow": "follow",
            "max-snippet": "max-snippet:-1",
            "max-image-preview": "max-image-preview:large",
            "max-video-preview": "max-video-preview:-1"
        },
        "canonical": "https:\/\/www.phinc-group.com\/fr\/equilibrer-lefficacite-et-la-securite-en-oncologie\/",
        "og_locale": "fr_FR",
        "og_type": "article",
        "og_title": "\u00c9quilibrer l'Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie - PhinC Group",
        "og_description": "Au cours de la derni\u00e8re d\u00e9cennie, le d\u00e9veloppement de m\u00e9dicaments en oncologie est pass\u00e9 d'une forte d\u00e9pendance \u00e0 la \u00ab dose maximale tol\u00e9r\u00e9e \u00bb (MTD) \u00e0 un encouragement actif des approches sur mesure inform\u00e9es par la mod\u00e9lisation. La FDA a officialis\u00e9 ses attentes par le biais d'initiatives sp\u00e9cifiques comme le Projet Optimus poussant \u00e0 une optimisation des doses qui \u00e9quilibre efficacit\u00e9 et toxicit\u00e9.",
        "og_url": "https:\/\/www.phinc-group.com\/fr\/equilibrer-lefficacite-et-la-securite-en-oncologie\/",
        "og_site_name": "PhinC Group",
        "article_published_time": "2026-11-12T18:56:19+00:00",
        "article_modified_time": "2026-11-12T20:48:55+00:00",
        "og_image": [
            {
                "width": 1000,
                "height": 750,
                "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/11\/visuel-efficacite-et-tolerance.png",
                "type": "image\/png"
            }
        ],
        "author": "Mohamed Taourirt",
        "twitter_card": "summary_large_image",
        "twitter_misc": {
            "\u00c9crit par": "Mohamed Taourirt",
            "Dur\u00e9e de lecture estim\u00e9e": "7 minutes"
        },
        "schema": {
            "@context": "https:\/\/schema.org",
            "@graph": [
                {
                    "@type": "Article",
                    "@id": "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/#article",
                    "isPartOf": {
                        "@id": "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/"
                    },
                    "author": {
                        "name": "Mohamed Taourirt",
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a"
                    },
                    "headline": "\u00c9quilibrer l&rsquo;Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie",
                    "datePublished": "2026-11-12T18:56:19+00:00",
                    "dateModified": "2026-11-12T20:48:55+00:00",
                    "mainEntityOfPage": {
                        "@id": "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/"
                    },
                    "wordCount": 1255,
                    "publisher": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#organization"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/#primaryimage"
                    },
                    "thumbnailUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/11\/visuel-efficacite-et-tolerance.png",
                    "articleSection": [
                        "A la une",
                        "Expertise"
                    ],
                    "inLanguage": "fr-FR"
                },
                {
                    "@type": "WebPage",
                    "@id": "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/",
                    "url": "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/",
                    "name": "\u00c9quilibrer l'Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie - PhinC Group",
                    "isPartOf": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#website"
                    },
                    "primaryImageOfPage": {
                        "@id": "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/#primaryimage"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/#primaryimage"
                    },
                    "thumbnailUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/11\/visuel-efficacite-et-tolerance.png",
                    "datePublished": "2026-11-12T18:56:19+00:00",
                    "dateModified": "2026-11-12T20:48:55+00:00",
                    "breadcrumb": {
                        "@id": "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/#breadcrumb"
                    },
                    "inLanguage": "fr-FR",
                    "potentialAction": [
                        {
                            "@type": "ReadAction",
                            "target": [
                                "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/"
                            ]
                        }
                    ]
                },
                {
                    "@type": "ImageObject",
                    "inLanguage": "fr-FR",
                    "@id": "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/#primaryimage",
                    "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/11\/visuel-efficacite-et-tolerance.png",
                    "contentUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/11\/visuel-efficacite-et-tolerance.png",
                    "width": 1000,
                    "height": 750
                },
                {
                    "@type": "BreadcrumbList",
                    "@id": "https:\/\/www.phinc-group.com\/equilibrer-lefficacite-et-la-securite-en-oncologie\/#breadcrumb",
                    "itemListElement": [
                        {
                            "@type": "ListItem",
                            "position": 1,
                            "name": "Accueil",
                            "item": "https:\/\/www.phinc-group.com\/en\/"
                        },
                        {
                            "@type": "ListItem",
                            "position": 2,
                            "name": "\u00c9quilibrer l&rsquo;Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie"
                        }
                    ]
                },
                {
                    "@type": "WebSite",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#website",
                    "url": "https:\/\/www.phinc-group.com\/fr\/",
                    "name": "PhinC Group",
                    "description": "Quantitative Pharmacology Solutions &amp; Modeling",
                    "publisher": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#organization"
                    },
                    "potentialAction": [
                        {
                            "@type": "SearchAction",
                            "target": {
                                "@type": "EntryPoint",
                                "urlTemplate": "https:\/\/www.phinc-group.com\/fr\/?s={search_term_string}"
                            },
                            "query-input": {
                                "@type": "PropertyValueSpecification",
                                "valueRequired": true,
                                "valueName": "search_term_string"
                            }
                        }
                    ],
                    "inLanguage": "fr-FR"
                },
                {
                    "@type": "Organization",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#organization",
                    "name": "PhinC Group",
                    "url": "https:\/\/www.phinc-group.com\/fr\/",
                    "logo": {
                        "@type": "ImageObject",
                        "inLanguage": "fr-FR",
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/",
                        "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg",
                        "contentUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg",
                        "width": 600,
                        "height": 600,
                        "caption": "PhinC Group"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/"
                    }
                },
                {
                    "@type": "Person",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a",
                    "name": "Mohamed Taourirt",
                    "image": {
                        "@type": "ImageObject",
                        "inLanguage": "fr-FR",
                        "@id": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "url": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "contentUrl": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "caption": "Mohamed Taourirt"
                    },
                    "url": "https:\/\/www.phinc-group.com\/fr\/author\/mtaourirt\/"
                }
            ]
        }
    },
    "_links": {
        "self": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5309",
                "targetHints": {
                    "allow": [
                        "GET"
                    ]
                }
            }
        ],
        "collection": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts"
            }
        ],
        "about": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/types\/post"
            }
        ],
        "author": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/users\/2"
            }
        ],
        "replies": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/comments?post=5309"
            }
        ],
        "version-history": [
            {
                "count": 5,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5309\/revisions"
            }
        ],
        "predecessor-version": [
            {
                "id": 5318,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5309\/revisions\/5318"
            }
        ],
        "wp:featuredmedia": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/media\/5314"
            }
        ],
        "wp:attachment": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/media?parent=5309"
            }
        ],
        "wp:term": [
            {
                "taxonomy": "category",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/categories?post=5309"
            },
            {
                "taxonomy": "post_tag",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/tags?post=5309"
            },
            {
                "taxonomy": "service-associe",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/service-associe?post=5309"
            }
        ],
        "curies": [
            {
                "name": "wp",
                "href": "https:\/\/api.w.org\/{rel}",
                "templated": true
            }
        ]
    }
}